Cantor Fitzgerald Forecasts MDGL FY2026 Earnings

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for Madrigal Pharmaceuticals in a report issued on Monday, June 9th. Cantor Fitzgerald analyst P. Agrawal anticipates that the biopharmaceutical company will post earnings of ($2.78) per share for the year. The consensus estimate for Madrigal Pharmaceuticals' current full-year earnings is ($23.47) per share.

A number of other equities research analysts also recently issued reports on MDGL. Canaccord Genuity Group boosted their price target on Madrigal Pharmaceuticals from $394.00 to $420.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. Wall Street Zen upgraded shares of Madrigal Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Monday, May 5th. HC Wainwright upped their price objective on Madrigal Pharmaceuticals from $400.00 to $405.00 and gave the stock a "buy" rating in a research note on Thursday, February 27th. B. Riley reiterated a "buy" rating and set a $460.00 target price (up from $422.00) on shares of Madrigal Pharmaceuticals in a research report on Friday, May 2nd. Finally, UBS Group raised their price objective on shares of Madrigal Pharmaceuticals from $441.00 to $458.00 and gave the company a "buy" rating in a research report on Friday, May 2nd. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, Madrigal Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus target price of $416.33.

Madrigal Pharmaceuticals Stock Performance

NASDAQ MDGL traded up $2.08 during trading hours on Tuesday, hitting $282.32. The company's stock had a trading volume of 143,415 shares, compared to its average volume of 369,321. Madrigal Pharmaceuticals has a 12 month low of $200.63 and a 12 month high of $377.46. The company's 50 day simple moving average is $299.01 and its two-hundred day simple moving average is $315.39. The company has a debt-to-equity ratio of 0.15, a current ratio of 5.98 and a quick ratio of 5.93. The company has a market cap of $6.27 billion, a P/E ratio of -11.26 and a beta of -1.08.

Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($3.32) EPS for the quarter, beating analysts' consensus estimates of ($3.62) by $0.30. The firm had revenue of $137.25 million for the quarter, compared to analysts' expectations of $112.79 million. During the same quarter in the previous year, the company earned ($7.38) EPS.

Hedge Funds Weigh In On Madrigal Pharmaceuticals

Several institutional investors have recently made changes to their positions in MDGL. VSM Wealth Advisory LLC purchased a new stake in shares of Madrigal Pharmaceuticals during the 1st quarter worth $25,000. Accent Capital Management LLC bought a new position in Madrigal Pharmaceuticals in the first quarter worth about $25,000. Summit Securities Group LLC bought a new position in Madrigal Pharmaceuticals in the first quarter worth about $33,000. Farther Finance Advisors LLC lifted its position in shares of Madrigal Pharmaceuticals by 825.0% during the first quarter. Farther Finance Advisors LLC now owns 111 shares of the biopharmaceutical company's stock valued at $36,000 after buying an additional 99 shares during the last quarter. Finally, GAMMA Investing LLC boosted its holdings in shares of Madrigal Pharmaceuticals by 131.4% in the 1st quarter. GAMMA Investing LLC now owns 118 shares of the biopharmaceutical company's stock valued at $39,000 after buying an additional 67 shares in the last quarter. Hedge funds and other institutional investors own 98.50% of the company's stock.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.